Abstract
OBJECTIVE: To investigate the possible association between response to levothyroxine (L-T4) doses in hypothyroid patients and variation in thyroid stimulating hormone receptor (TSHR) gene and thyroid hormone receptor (THRα) gene. DESIGN: This cross-sectional correlation study included 228 patients with primary hypothyroidism who were using L-T4 replacement therapy. Thyroid function test was performed using standard techniques. Genotyping of rs939348 of the THRα gene, and rs2268458 and rs2239610 of the TSHR gene was performed using the polymerase chain reaction-based restriction fragment length polymorphism assay (PCR-RFLP). Patient history of illness, medication and compliance data were collected using the patients’ medical files. RESULTS: The THRα rs939348 polymorphism was associated with L-T4 replacement doses in hypothyroid patients and in central obesity. No significant correlation was detected between the examined SNPs to TSHR and L-T4 doses or the different clinical and biochemical parameters. Finally, L-T4 dose was associated with lower BMI, waist circumference and TSH, and higher free T4 (fT4) among hypothyroid patients. CONCLUSIONS: Whereas the two tested TSHR polymorphisms were not associated with the dose of T4, the THRα rs939348 polymorphism was associated with L-T4 dose and central obesity among hypothyroid patients. T4 dose was also associated with multiple beneficial effects among hypothyroid patients.
Article PDF
Similar content being viewed by others
References
Todd CH, 2009 Management of thyroid disorders in primary care: challenges and controversies. Postgrad Med J 85: 655–659.
Baskin HJ, Cobin RH, Duick DS, et al, 2002 American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 8: 457–469.
Vaidya B, Pearce SH, 2008 Management of hypothyroidism in adults. BMJ 337: a801.
Zhang J, Lazar MA, 2000 The mechanism of action of thyroid hormones. Annu Rev Physiol 62: 439–466.
Louwerens M, Appelhof BC, Verloop H, et al, 2012 Fatigue and fatigue-related symptoms in patients treated for different causes of hypothyroidism. Eur J Endocrinol 167: 809–815.
Peeters RP, van der Deure WM, Visser TJ, 2006 Genetic variation in thyroid hormone pathway genes; polymorphisms in the TSH receptor and the iodothyronine deiodinases. Eur J Endocrinol 155: 655–662.
Zulewski H, Muller B, Exer P, Miserez AR, Staub JJ, 1997 Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. J Clin Endocrinol Metab 82: 771–776.
Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ Jr, 1999 Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 340: 424–429.
Checchi S, Montanaro A, Pasqui L, et al, 2008 L-thyroxine requirement in patients with autoimmune hypothyroidism and parietal cell antibodies. J Clin Endocrinol Metab 93: 465–469.
Escobar-Morreale HF, Botella-Carretero JI, Gomez-Bueno M, et al, 2005 Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med 142: 412–424.
Jonklaas J, 2009 Gender and age differences in levothyroxine dose requirement. Endocrine Practice 15: 1–23.
Levothyroxine drug information provided by Lexi-Comp 2010 [cited 2010 18 June 2010].
Peeters RP, van Toor H, Klootwijk W, et al, 2003 Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. J Clin Endocrinol Metab 88: 2880–2888.
Kim BW, Bianco AC, 2009 For some, L-thyroxine replacement might not be enough: a genetic rationale. J Clin Endocrinol Metab 94: 1521–1523.
Al-Azzam SI, Alkhateeb AM, Al-Azzeh O, Alzoubi KH, Khabour OF, 2013 The Role of Type II Deiodinase Polymorphisms in Clinical Management of Hypothyroid Patients Treated with Levothyroxine. Exp Clin Endocrinol Diabetes 121: 300–305.
Lin JZ, Sieglaff DH, Yuan C, et al, 2013 Gene specific actions of thyroid hormone receptor subtypes. PLoS One 8: e52407.
Brent G A, 2012 Mechanisms of thyroid hormone action. J Clin Invest 122: 3035–3043.
Peeters RP, van der Deure WM, Visser TJ, 2006 Genetic variation in thyroid hormone pathway genes; polymorphisms in the TSH receptor and the iodothyronine deiodinases. Eur J Endocrinol 155: 655–662.
Rebai M, Kallel I, Rebai A, 2012 Genetic features of thyroid hormone receptors. J Genet 91: 367–374.
Goumidi L, Gauthier K, Legry V, et al, 2011 Association between a thyroid hormone receptor-alpha gene polymorphism and blood pressure but not with coronary heart disease risk. Am J Hypertens 24: 1027–1034.
Schaffler A, 2010 Hormone replacement after thyroid and parathyroid surgery. Dtsch Arztebl Int 107: 827–834.
Lizcano F, Rodriguez JS, 2011 Thyroid hormone therapy modulates hypothalamo-pituitary-adrenal axis. Endocr J 58: 137–142.
Katzung BG, Trevor A J, 2010 Basic & Clinical Pharmacology. McGraw-Hill Medical.
Arnaud-Lopez L, Usala G, Ceresini G, et al, 2008 Phosphodiesterase 8B gene variants are associated with serum TSH levels and thyroid function. Am J Hum Genet 82: 1270–1280.
Dechairo BM, Zabaneh D, Collins J, et al, 2005 Association of the TSHR gene with Graves’ disease: the first disease specific locus. Eur J Hum Genet 13: 1223–1230.
Cerbone M, Agretti P, De Marco G, et al, 2013 Non-autoimmune subclinical hypothyroidism due to a mutation in TSH receptor: report on two brothers. Ital J Pediatr 39: 5.
Yin X, Latif R, Bahn R, Tomer Y, Davies TF, 2008 Influence of the TSH receptor gene on susceptibility to Graves’ disease and Graves’ ophthalmopathy. Thyroid 18: 1201–1206.
Gu LQ, Zhu W, Zhao SX, et al, 2010 Clinical associations of the genetic variants of CTLA-4, Tg, TSHR, PTPN22, PTPN12 and FCRL3 in patients with Graves’ disease. Clin Endocrinol (Oxf) 72: 248–255.
Gharibeh MY, Al Tawallbeh GM, Abboud MM, et al, 2010 Correlation of plasma resistin with obesity and insulin resistance in type 2 diabetic patients. Diabetes Metab 36: 443–449.
Al-Azzam SI, Alkhateeb AM, Al-Azzeh O, Alzoubi KH, Khabour OF, 2013 The role of type II deiodinase polymorphisms in clinical management of hypothyroid patients treated with levothyroxine. Exp Clin Endocrinol Diabetes 121: 300–305.
Hueston WJ, 2001 Treatment of hypothyroidism. Am Fam Physician 64: 1717–1724.
dbSNP provided by Medline database
The human genome browser at UCSC Genome, 2000 USCS Genome Bioinformatics.
Rozan S, Skaletsky H 2000 Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S (eds) Bioinformatics Methods and Protocols: Methods in Molecular Biology, Humana Press, Totowa, NJ, pp, 365–386.
Vincze T, Posfai J, Roberts RJ, 2003 NEBcutter: A program to cleave DNA with restriction enzymes. Nucleic Acids Res 31: 3688–3691.
Restriction Mapper: Maps sites for restriction enzymes, a.k.a. restriction endonucleases, in DNA sequences.
Ruhla S, Weickert MO, Arafat AM, et al, 2010 A high normal TSH is associated with the metabolic syndrome. Clin Endocrinol (Oxf) 72: 696–701.
Pearce EN, 2012 Thyroid hormone and obesity. Curr Opin Endocrinol Diabetes Obes 19: 408–413.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Al-Azzam, S.I., Alzoubi, K.H., Khabour, O. et al. The associations of polymorphisms of TSH receptor and thyroid hormone receptor genes with L-thyroxine treatment in hypothyroid patients. Hormones 13, 389–397 (2014). https://doi.org/10.14310/horm.2002.1488
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1488